GCFC2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes in which the gene encoding GCFC2 has been disrupted to create a loss-of-function model. This knockout product format provides a genetically heterogeneous pool of cells with targeted ablation of GCFC2 expression, enabling robust functional studies without clonal selection artifacts. The product is designed for researchers investigating transcriptional regulation and apoptotic signaling in B-cell malignancies. By abolishing GCFC2??s DNA-binding and putative histone methyltransferase activities, the model permits systematic dissection of its role in gene expression control within a lymphoblastoid background.
The Raji cell line, originally isolated from a patient with Burkitt??s lymphoma, is an Epstein-Barr virus (EBV)-positive, B-lymphoblastoid suspension culture widely employed as a model of aggressive B-cell neoplasms. These cells harbor the characteristic t(8;14) chromosomal translocation that juxtaposes the MYC oncogene with immunoglobulin enhancer elements, leading to constitutive MYC overexpression and potent proliferative drive. Retaining features of germinal center B cells, Raji cells serve as a tractable system for studying oncogenic signaling, antigen presentation, and viral latency. Their lymphoblast-like morphology and suspension growth facilitate high-throughput functional assays.
GCFC2 (GC-rich sequence DNA-binding factor 2) functions as a transcriptional repressor that recognizes GC-rich promoter elements, often competing with the activator SP1. Through its SET domain, GCFC2 is thought to mediate histone methylation, facilitating recruitment of histone deacetylases (HDACs) and transcriptional co-repressors to silence target gene expression. In B-lymphoma cells, this activity modulates key downstream effectors such as CDKN1A (p21), BAX, and BCL2 family members, thereby governing cell cycle progression and apoptotic sensitivity. Upstream, GCFC2 is subject to regulation by cell cycle kinases and may be influenced by the aberrant MYC signaling characteristic of Raji cells, which perturbs the SP1/GCFC2 equilibrium at shared promoters. The GCFC2 knockout disrupts this repressive axis, leading to derepression of pro-apoptotic and antiproliferative genes.
In the MYC-deregulated, EBV-positive Raji environment, loss of GCFC2 removes a transcriptional brake on regulatory networks controlling cell proliferation and survival. The resultant upregulation of p21 and pro-apoptotic BCL2 family members shifts the cellular balance toward cell cycle arrest and apoptosis, offering a powerful platform to examine how B-cell lymphomas evade growth-suppressive signals. This polyclonal knockout model is particularly relevant for dissecting the interplay between viral latency programs, MYC-driven transcription, and host repressor mechanisms. It can be used to evaluate whether GCFC2 functions as a tumor suppressor or a context-dependent modulator in aggressive B-cell malignancies, including Burkitt??s lymphoma and diffuse large B-cell lymphoma.
Researchers can apply GCFC2 Knockout Raji Polyclonal Cells to a variety of experimental workflows, including transcriptome profiling via RNA-seq, chromatin occupancy studies with ChIP-qPCR, and functional validation of target gene expression by RT-qPCR and Western blotting. Flow cytometry enables quantitative cell cycle and apoptosis readouts, while CFU and drug sensitivity assays allow assessment of chemotherapeutic response in the absence of GCFC2-mediated repression. These cells also serve as a platform for screening small molecules that modulate the SP1/GCFC2 regulatory axis or for validating GCFC2 as a therapeutic target in B-cell leukemia and lymphoma contexts. For technical inquiries and ordering information, please contact Ascent Research.
